By Joshua M. Sharfstein
Sharfstein served as Deputy Commissioner at FDA from March 2009 until January 2011, when he left the agency to run...
Fostering Trust at FDA
Joshua Sharfstein left his post as principle deputy commissioner of the Food & Drug Administration in January, leaving behind a short but productive legacy of increasing the level of transparency at FDA. Just before he left to become Maryland’s Secretary of Health and Mental Hygiene, he discussed transparency at the FDA/CMS Summit for Biopharmaceutical Executives. Here are excerpts from Sharfstein’s speech.
More from Archive
• By
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
• By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
• By
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
• By
The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.
• By
Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.
• By
The UK government is making it easier for millions of people to participate in clinical trials and is boosting transparency around how studies are delivered across the National Health Service.